- Opinion
- [Reporter's view] A plan to expand the reference country
- by Lee, Tak-Sun Dec 8, 2022 06:05am
- The pharmaceutical industry is strongly opposed to the government's plan to expand drug price reference countries. Although the Ministry of Health and Welfare says it has gone through a sufficient discussion process, the industry is strongly criticizing it as a one-sided push. The revision of the HIRA's administrative notice on the 21st of la
- Company
- Immunotherapy shows effect as first-line treatment for BTC
- by Dec 8, 2022 06:05am
- Biliary tract cancer has long remained an area in which no new drug has been developed. Following targeted therapies, immunotherapies have led to remarkable advances in anticancer treatment, but biliary tract cancer has been neglected in terms of developing new drugs. This is because it has a lower prevalence rate than other cancers like lung ca
- Product
- MFDS' statement of consent to Rx of the active ingredients
- by Kang, Shin-Kook Dec 7, 2022 05:55am
- While Oh Yoo-kyung, the head of the Ministry of Food and Drug Safety, said, "I agree" with the prescription of the ingredient name, he took a step back, saying in an official letter sent by the Ministry of Food and Drug Safety to the doctors' organization. According to an official letter sent by the Ministry of Food and Drug Safety to the Kor
- Policy
- Only K-CAB continues to be applied refund-type PVA
- by Lee, Tak-Sun Dec 7, 2022 05:55am
- HK Inno.N’s ‘K-CAB Tab’ is the only drug that is applied the refund-type Price-Volume Agreement (PVA) system in Korea. The fact that the system is only applied to homegrown new drugs, and some companies do not prefer double pricing caused by refunds are pointed to as reasons for the low utilization rate of the PVA system. The Natio
- Policy
- Vaccine sales reached 3.4178 trillion won in Korea last year
- by Lee, Hye-Kyung Dec 7, 2022 05:55am
- About half of the companies complain of difficulties due to lack of funds in the research and commercialization process. Last year, domestic sales in the vaccine industry totaled 3.4178 trillion won and exports amounted to 628.7 billion won. The Ministry of Health and Welfare (Minister Cho Kyu-hong) and the Ministry of Trade, Industry, and
- Policy
- Reimb of antidiabetic SGLT-2+DPP-4 combo near
- by Kim, Jung-Ju Dec 7, 2022 05:55am
- Expanding reimbursement to the combined use of SGLT-2 inhibitors and DPP-4 inhibitors as treatment for diabetes has entered its final stages. As the reimbursement will be carried out through voluntary price cuts by pharmaceutical companies as intended by the government, the process may proceed faster than when companies take the drug pri
- Company
- Oral Exon20 targeted Exkivity to apply for reimb in Korea
- by Eo, Yun-Ho Dec 6, 2022 07:55pm
- The EGFR Exon20 insertion mutation targeted oral therapy ‘Exkivity’ is attempting reimbursement listing in Korea. According to industry sources, Takeda Pharmaceuticals Korea is preparing to apply for reimbursement of ‘Exkivity (mobocertinib), its treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
- Policy
- One-shot Zolgensma fulfills terms of its RSA contract
- by Kim, Jung-Ju Dec 6, 2022 05:57am
- Zolgensma (onasemnogene abeparvovec), the ultra-high-priced ‘one-shot treatment’ that succeeded in receiving reimbursement in Korea in May this year, will start fulfilling the terms of its risk-sharing agreements (RSA) contract. If the drug was administered at the time its reimbursement was approved in Korea, the medical institutions t
- Company
- ImmuneOncia targets niche market in cancer immunotherapy
- by Dec 6, 2022 05:57am
- “NK/T-cell lymphoma is a niche market that has no approved immunotherapy. After completing the trial in Q2 next year, we plan to promptly receive approval and extend our indication if we see good results.“ On the 3rd (local time), Heung Tae Kim, CEO of ImmuneOncia Therapeutics, expressed his aspirations at the ‘ESMO Asia Congress 2022
- Company
- Concerns over Leclaza's sluggish secondary indicators
- by Dec 6, 2022 05:57am
- This is in contrast to the significant improvement in the primary indicator, the progression-free survival period (PFS). We cannot rule out the possibility that a similar situation to Tagrisso, whose effectiveness was questioned by the Asian OS, will be reproduced. The global clinical director (PI) explains that it is not easy to secure stati
